Skip to content
Life Sciences Series B Founded 2003

OncoMethylome

Diagnostics for early detection of cancer. OncoMethylome develops diagnostic tests for the early detection of cancer. It specializes in the development of assays based on methylation-specific PCR (PCR) that detects abnormal DNA methylation pathways. It is currently developing tests for prostate, bladder, colorectal, breast and cervical cancers. Founded in 2003, headquartered in Antwerp, Belgium. The company operates…

📍 Antwerp, Belgium · Genomics,

Funding snapshot

Last roundSeries B
Amount$18M
Date4 November 2005
Total raised$34M
Team size6

About

Diagnostics for early detection of cancer. OncoMethylome develops diagnostic tests for the early detection of cancer. It specializes in the development of assays based on methylation-specific PCR (PCR) that detects abnormal DNA methylation pathways. It is currently developing tests for prostate, bladder, colorectal, breast and cervical cancers. Founded in 2003, headquartered in Antwerp, Belgium. The company operates in the Life Sciences > Genomics, Life Sciences > Oncology sector. Founded in 2003 and headquartered in Antwerp, Belgium and has raised $33.9 million in Series B funding. Key investors include PolyTechnos Venture Partners, Edmond de Rothschild, ING, Life Sciences Partners, Noshaq, EQT.

Business model

Oncology > In-Vitro Diagnostic Tests > Pan Cancer,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Epigenomics

Institutional investors

PolyTechnos Venture Partners Edmond de Rothschild ING Life Sciences Partners Noshaq EQT

Latest coverage

No articles yet.

Raising like OncoMethylome?

Analyze your pitch deck before your next raise.

Analyze My Deck →